Profil Institute to Present at the American Diabetes Association’s 74th Annual Scientific Sessions in San Francisco

Profil Institute to Present at the American Diabetes Association’s 74th Annual Scientific Sessions in San Francisco

SAN DIEGO, June 9, 2014 – Profil® Institute for Clinical Research, Inc., an early phase clinical research organization focused on diabetes and obesity, announced today presentations by CEO Dr. Marcus Hompesch and COO Dr. Linda Morrow at the American Diabetes Association’s (ADA) 74th Scientific Sessions.

This year’s ADA Scientific Sessions will take place June 13-17 in San Francisco.  The conference is hosted by the American Diabetes Association, bringing together more than 14,000 clinicians and researchers from all 50 states and 111 countries.  Key scientists and directors from Profil Institute will attend this year’s ADA Scientific Sessions and will be available during the conference at booth #2307.

Profil Institute presentations at the ADA’s Scientific Sessions include the following:

Invited Talk:

  • Biosimilars – Opportunities and Challenges
    Presenter: Dr. Marcus Hompesch, Profil Institute President and CEO
    Session: The Need for a Better Basal – What’s on the Horizon
    Location: S-307 (South Building)
    Saturday, Jun 14, 5:00 PM

Poster Presentations:

  • The Ultra-Long-Acting Insulin HM12460A Demonstrates Safety and Efficacy in Patients with Type 1 Diabetes: A Phase 1 Single Dose Explorative Glucose Clamp Study
    Poster number: 894-P
    Category: 01-B Clinical Therapeutics/New Technology–Insulins
    Session: Saturday General Poster
    Saturday, Jun 14, 11:30 AM – 1:30 PM, Poster Hall (Hall D-North)
  • The Ultra-Long-Acting Insulin HM12460A Demonstrates Safety and Efficacy in Patients with Type 2 Diabetes: A Phase 1 Single Dose Explorative Glucose Clamp Study
    Poster number: 895-P
    Category: 01-B Clinical Therapeutics/New Technology – Insulins
    1st Session: Saturday General Poster
    Saturday, Jun 14, 11:30 AM – 1:30 PM, Poster Hall (Hall D-North)
    2nd Session: Guided Audio Tours – Pharmacokinetic and Pharmacodynamic Insulin Studies
    Monday, Jun 16, 1:00 – 2:00 PM, Poster Hall (Hall D-North)
  • A Long-Acting Exendin-4 Analog Conjugate to the Human Fc-fragment Reveals Low Immunogenic Potential
    Poster number: 1009-P
    Category: 01-D Clinical Therapeutics/New Technology – Non-Insulin Injectables
    Session: Saturday General Poster
    Saturday, Jun 14, 11:30 AM – 1:30 PM, Poster Hall (Hall D-North)
  • Concentrated Insulin BIOD-531 Is Associated with Accelerated Onset of Action Compared to Humulin® R U-500 and Humalog® Mix75/25™ and a Basal Duration Profile
    Poster number: 82-LB
    Category: 01-B Clinical Therapeutics/New Technology–Insulins
    Session: Late Breaking Studies
    Sunday, Jun 15, 12:00 – 2:00 PM, Poster Hall (Hall D-North)
  • A Novel Very Long-Acting Insulin Analog (HM12470) with Potential for Once-Weekly Dosing, Has a Favorable PK, PD and Mitogenic Profile
    Presentation number: 89-LB
    Category: 01-B Clinical Therapeutics/New Technology – Insulins
    Session: Late Breaking Studies
    Sunday, Jun 15, 12:00 – 2:00 PM, Poster Hall (Hall D-North)
  • Lipolytic and Insulinotropic Effects of HM12525A, a Novel Long-acting GLP-1/Glucagon Dual Agonist
    Poster number: 116-LB
    Category: 01-D Clinical Therapeutics/New Technology – Non-Insulin Injectable
    Session: Late Breaking Studies
    Sunday, Jun 15, 12:00 – 2:00 PM, Poster Hall (Hall D-North)
  • Glimepiride Delays Recovery from Hypoglycemia in Subjects with Type 2 Diabetes Mellitus
    Number: 2226-PO (published only)
    Category: 02 Complications–Hypoglycemia

More information about conference presentations by Profil Institute scientists is available on the company’s website at www.profilinstitute.com/news-events/conferences/.

About Profil® Institute for Clinical Research, Inc.

Profil Institute for Clinical Research, Inc. is a science driven, early phase clinical research organization focused on diabetes and obesity.  The company is renowned as a center of excellence for metabolic clinical research and development based on its scientific expertise, depth of services, and research methodologies. Operational since 2004, Profil Institute is a trusted partner and service provider for its clients from small virtual companies to large pharma and drug discovery companies, as well as academic centers, throughout the Americas, Europe and Asia.

Profil Institute works with clients to design and execute first-in-human, proof of mechanism clinical research for metabolic drug and device candidates.  To date, Profil Institute has completed more than 200 phase I-IIa diabetes and obesity clinical studies, involving every clinically relevant diabetes drug class and a wide array of medical devices.  In addition to clinical research, Profil Institute provides early phase clinical development services and consulting, including the design of strategic clinical development plans and management of regulatory affairs.  For more information visit www.profilinstitute.com.

For further information, please contact:

Abby Devine
Corporate Communications
abby.devine@profilinstitute.com
858-663-6148